[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  SEC Filings Digest [@USCorpFilings](/creator/twitter/USCorpFilings) on x 4305 followers Created: 2025-07-16 21:45:09 UTC $FBIO Regulatory Compliance: On July 16, 2025, Fortress Biotech, Inc. reported AstraZeneca's update stating that its product anselamimab did not meet primary goals in a clinical trial for AL amyloidosis, despite some clinical benefits seen in a specific patient group. Fortress had previously received $XX million from the acquisition of Caelum Biosciences and could earn more based on future milestones. XXX engagements  **Related Topics** [acquisition](/topic/acquisition) [regulatory](/topic/regulatory) [$fbio](/topic/$fbio) [Post Link](https://x.com/USCorpFilings/status/1945600617504018521)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
SEC Filings Digest @USCorpFilings on x 4305 followers
Created: 2025-07-16 21:45:09 UTC
$FBIO Regulatory Compliance:
On July 16, 2025, Fortress Biotech, Inc. reported AstraZeneca's update stating that its product anselamimab did not meet primary goals in a clinical trial for AL amyloidosis, despite some clinical benefits seen in a specific patient group. Fortress had previously received $XX million from the acquisition of Caelum Biosciences and could earn more based on future milestones.
XXX engagements
Related Topics acquisition regulatory $fbio